E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE) |
|
E.1.1.1 | Medical condition in easily understood language |
Blockage in the pulmonary artery, the blood vessel that carries blood from the heart to the lungs |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10037379 |
E.1.2 | Term | Pulmonary embolism and thrombosis |
E.1.2 | System Organ Class | 100000004866 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037377 |
E.1.2 | Term | Pulmonary embolism |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to assess the safety and tolerability of ascending doses of DS-1040b given as a single intravenous (IV) infusion over 12, 24, 48 and 72 hours (h), respectively, when added to standard of care (SOC) anticoagulation therapy compared to placebo by evaluating the rate of clinically relevant bleeding ie, major or clinically relevant non-major [CRNM] bleeding (adjudicated by the Clinical Events Committee [CEC] based on the International Society of Thrombosis and Haemostasis [ISTH] definitions). |
|
E.2.2 | Secondary objectives of the trial |
1. Relative reduction in total thrombus volume from baseline to ≤ 12h from end of DS-1040b infusion, assessed by CTA in segmental/larger pulmonary arteries;
2. Proportion of subjects who achieve a ≥ 20% greater relative reduction in total thrombus volume assessed by CTA in segmental/larger pulmonary arteries, from baseline to ≤ 12h from end of DS-1040b infusion and compared to placebo;
3. Proportion of subjects who achieve a ≥ 50% greater relative reduction in total thrombus volume assessed by CTA in segmental/larger pulmonary arteries, from baseline to ≤ 12h from end of DS-1040b infusion compared to placebo;
4. Recurrence of VTE up to hospital discharge and up to Day 30 Visit after dosing;
5. Adjudicated death, major cardiovascular events, hemodynamic decompensation, treatment escalation up to hospital discharge and up to D30 Visit after dosing;
6. Overall safety evaluation;
7. Pharmacokinetics of DS-1040b;
8. Assess the PD effect of DS-1040b on biomarkers, in subjects with PE. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female subjects, age 18 to 75 years and body weight between 50 and 130 kg, inclusive;
2. Subjects admitted to the hospital with a clinical diagnosis of acute PE with an onset of symptoms in the 5 days prior to diagnosis categorized as low risk or intermediate-risk or submassive PE and for whom catheter-based therapy is not planned;
a. Subjects must have a CTA scan confirming the PE diagnosis and with at least one measurable index lesion in a segmental or larger pulmonary artery prior to randomization;
b. Subjects should be in otherwise satisfactory health in the opinion of the Investigator;
c. Subjects may have concurrent DVT and have an inferior vena cava (IVC) filter placed prior to randomization;
d. Subjects may already be on SOC low molecular weight LMW heparin at the time of randomization but for no longer than 36 hours.
3. Able to provide written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Subjects with acute PE categorized as high-risk or massive, or who are hemodynamically unstable, evidenced by a heart rate > 120 /min and a systolic blood pressure (SBP) of < 90 mmHg for more than 15 consecutive minutes or a drop in SBP of > 40 mmHg since presentation;
2. Subjects for whom use of a thrombolytic, either systemic or via catheter, is planned;
3. Subjects with PE lesions only in the sub-segmental or smaller arteries, which due to limitations of the imaging method may not be consistently identified and measured;
4. Subjects unable or unwilling to take the required SOC anticoagulation therapy;
5. Subjects receiving more than 36 hours of SOC anticoagulants for treatment of the index PE event prior to randomization. Study drug infusion will ideally begin within 6hr after randomization
6. Subjects who had prior intracranial hemorrhage, known arteriovenous malformation or aneurysm, or evidence of active bleeding;
7. Subjects with bleeding diathesis, a platelet count < 100,000, international normalized ratio (INR) > 1.7, or clinically significant elevated activated partial thromboplastin time (aPTT) that is not explained by use of LMW heparin;
8. Subjects with active endocarditis;
9. Subjects with < 6 month history of acute coronary syndrome (ACS) whether or not they have undergone percutaneous coronary intervention (PCI);
10. Subjects who require ongoing dual antiplatelet therapy or treatment with aspirin alone in a dosage of more than 100 mg/per day;
11. Chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) including both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors for ≥ 4 days/week anticipated to continue during the study;
12. Subjects with uncontrolled hypertension at randomization, evidenced by systolic blood pressure > 180 mm Hg or diastolic blood pressure>120 mmHg, or who require parenteral medication to maintain blood pressure below these limits;
13. Subjects who within 3 months prior to randomization have had intracranial surgery, clinically significant head trauma (in the opinion of the Principal Investigator), a stroke, or have received thrombolytic treatment;
14. Subjects with ECG evidence of 2nd degree or higher atrioventricular (AV) block or with QTcB or QTcF >450 ms;
15. Subjects who within 21 days prior to randomization have had gastrointestinal or genitourinary bleeding;
16. Subjects who within 14 days prior to randomization have had major surgery or a lumbar puncture (or epidural steroid injection);
17. Subjects with hemoglobin < 10 g/dL;
18. Subjects with an estimated creatinine clearance < 60 mL/min;
19. Subjects with diagnosed active liver disease or with elevation of liver enzymes/bilirubin:
a. Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 2 times upper limit of normal (ULN)
b. Total bilirubin (TBL) ≥ 1.5 times ULN (except due to confirmed Gilbert’s syndrome)
20. Subjects with known history of testing positive for Hepatitis B antigen or Hepatitis C antibody before randomization;
21. Subjects with known history of testing positive for the human immunodeficiency virus (HIV);
22. Subjects with active cancer, defined as recurrent, regionally advanced, metastatic disease, or a hematologic malignancy not in complete remission and subjects with malignancy diagnosed within 2 years prior to randomization, except for adequately treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm;
23. Subjects currently receiving chemotherapy or radiation therapy or having received any treatment for cancer during the 12 months prior to randomization, or expected to initiate such therapy during study participation;
24. Subjects with NYHA Class III or IV congestive heart failure;
25. Subjects with chronic obstructive pulmonary disease;
26. Female subjects of child bearing potential with a positive pregnancy test, lactating women or women unwilling to use highly effective methods of birth control. Highly effective methods of birth control include combination hormonal therapy (estrogen and progesterone), contraceptives administered orally, intravaginally or transdermally, progesterone-only contraceptives administered orally, by injection or implantation, use of an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, partner vasectomy or sexual abstinence.
27. Subjects currently participating in another investigational study or who have participated in an investigational drug study within 30 days or prior to randomization;
28. Subjects unlikely to comply with the protocol (eg, uncooperative attitude, inability to return for subsequent visits, and/or otherwise considered by the investigator to be unlikely to complete the study);
29. Subjects with any condition (including laboratory abnormalities) that, in the opinion of the Investigator, would potentially place the subject at increased risk of harm through participation in this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy:
1. Relative reduction (% reduction) in total thrombus volume from baseline to ≤ 12h from end of DS-1040b infusion assessed by CTA) in segmental or larger pulmonary arteries;
2. Proportion of subjects who achieve a ≥ 20% greater relative reduction in total thrombus volume assessed by CTA in segmental or larger pulmonary arteries, from baseline to ≤ 12h from end of DS-1040b infusion;
3. Proportion of subjects who achieve a ≥ 50% greater relative reduction in total thrombus volume assessed by CTA in segmental or larger pulmonary arteries, from baseline to ≤ 12h from end of DS-1040b infusion.
Safety:
1. Clinically relevant bleeding (adjudicated major or CRNM bleeding);
2. Serious adverse events and TEAEs.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
All Efficacy: Baseline to ≤ 12h from end of infusion
All Safety: Continuous through the study |
|
E.5.2 | Secondary end point(s) |
Efficacy:
1. Recurrence of VTE (Composite of recurrent symptomatic PE, new or recurrent symptomatic DVT, VTE-related death; as well as the individual components) up to hospital discharge and up to Day 30 Visit;
2. Death, hemodynamic decompensation, or treatment escalation (defined as catecholamine infusion, secondary thrombolysis, endotracheal intubation, cardiopulmonary resuscitation, or emergency surgical embolectomy or thrombus fragmentation by catheter) up to hospital discharge and up to Day 30 post randomization;
3. MACE (defined as a composite of cardiovascular death, or non-fatal myocardial infarction, stroke, or SEE) up to hospital discharge and up to Day 30 Visit.
PK/PD:
1. Plasma concentrations of DS-1040a:
2. Pharmacodynamic endpoints including:
a. total TAFIa activity;
b. D-dimer;
c. TAFI antigen; |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All Efficacy: Up to hospital discharge and up to Day 30 Visit
PK/PD:
1. - Area under concentration-versus-time curve, from time 0 to the last quantifiable concentration sampling point (AUClast) and from time 0 extrapolated to infinity (AUC0-inf), if data allows
- Maximum (peak) observed plasma concentration (Cmax);
- Time of maximum observed concentration (Tmax);
- Immediately prior to the end of continuous infusion;
- Elimination half-life (T1/2), if data allows
- Total clearance (CL), if data allows
2. The following for a,b&c:
All cohorts (C): Baseline (predose), 0.5 (end of loading infusion) plus:
C1: 6, 12 (end of maintenance infusion - EoMI), 18, 24 & 48 hrs
C2&3: 24 (EoMI), 36, 48 & 72 hrs
C4&5: 48 (EoMI), 60, 72 & 96 hrs
C6: 72 (EoMI), 84, 96 & 120 hrs |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 35 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Belgium |
France |
Germany |
Italy |
Netherlands |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |